

27 November 2009

## **RESOLUTIONS PASSED AT ANNUAL GENERAL MEETING**

At the Annual General Meeting of Biomedical company, **Tissue Therapies Limited (ASX: TIS)** held on 27 November 2009 the following resolutions were passed on a show of hands:

**2. Directors' Remuneration Report**

*'That the section of the Directors' Report dealing with the remuneration of the Company's Directors, Company Secretary and Senior Executives (**Remuneration Report**) be adopted.'*

**3. Re-election of Melvyn Bridges**

*'That Melvyn Bridges, who was appointed to fill a casual vacancy and retires in accordance with Listing Rule 14.4 and Rule 13.2 of the Company's Constitution, and being eligible, be re-elected as a Director of the Company.'*

**4. Re-election of Dr Cherrell Hirst**

*'That Dr Cherrell Hirst who was appointed to fill a casual vacancy and retires in accordance with Listing Rule 14.4 and Rule 13.2 of the Company's Constitution, and being eligible, be re-elected as a Director of the Company.'*

**5. Re-election of Gregory Baynton**

*'That Gregory Baynton, who retires in accordance with Listing Rule 14.4 and Rule 16.1 of the Company's Constitution, and being eligible, and having offered himself for re-election, be re-elected as a Director of the Company.'*

**6. Re-election of Roger Clarke**

*'That Roger Clarke, who retires in accordance with Listing Rule 14.4 and Rule 16.1 of the Company's Constitution, and being eligible, and having offered himself for re-election, be re-elected as a Director of the Company.'*

**7(a) Ratification and Approval of Previous Issue of Shares under Initial Placement**

*'That for the purposes of Listing Rule 7.4 and for all other purposes, approval be given for the previous issue of 11,720,723 shares at an issue price of \$0.15 per share, issued under the initial placement to sophisticated and institutional investors (introduced by the lead manager, RBS Morgans Limited) as detailed in the Explanatory Memorandum attached to this Notice of Meeting.'*

**7(b) .Approval of Issue of Shares under Conditional Share Purchase Plan**

*‘‘That for the purposes of Listing Rule 7.1 and for all other purposes, approval be given for the issue and allotment of up to approximately 23,441,447 shares at an issue price of the lesser of \$0.15 per share or 80% of the average closing price on the last 5 trading days prior to the date of issue of shares under the conditional Share Purchase Plan as detailed in the Explanatory Memorandum attached to this Notice of Meeting.’*

**7(c) Approval of Issue of Shares under Follow-on Placement**

*‘That for the purposes of Listing Rule 7.1 and for all other purposes, approval be given for the issue and allotment of 21,612,611 shares at an issue price of \$0.15 per share, to be issued under a follow-on share placement made to sophisticated and institutional investors (introduced by the lead manager, RBS Morgans Limited) as detailed in the Explanatory Memorandum attached to this Notice of Meeting.’*

**7(d) Approval of Issue of Shares to Directors under Conditional Share Purchase Plan**

*‘That for the purposes of Listing Rule 10.11 and for all other purposes, that approval be given for the issue of ordinary shares to directors who choose to participate in the conditional Share Purchase Plan as detailed in the Explanatory Memorandum attached to this Notice of Meeting.’*

**7(e) Approval of Issue of Placement Shares to Directors**

*‘That for the purposes of Listing Rule 10.11 and for all other purposes, that approval be given for the issue of ordinary shares on the terms of the placement made to sophisticated and institutional shareholders as detailed in the Explanatory Memorandum attached to the Notice of Meeting, to directors (or their associates) who participate in the Placement.’*

**Summary of Proxy Votes Lodged**

| <b>Resolution Name</b> | <b>For</b> | <b>At Discretion of Proxy Holder</b> | <b>Against</b> | <b>Abstain</b> |
|------------------------|------------|--------------------------------------|----------------|----------------|
| 2                      | 25,720,626 | 1,124,055                            | 366,295        | 973,585        |
| 3                      | 26,936,091 | 1,186,055                            | 19,764         | 42,651         |
| 4                      | 26,903,035 | 1,186,055                            | 52,820         | 42,651         |
| 5                      | 26,320,392 | 1,186,055                            | 16,764         | 661,350        |
| 6                      | 20,182,142 | 7,977,005                            | 16,764         | 8,650          |
| 7(a)                   | 26,762,748 | 1,195,412                            | 154,770        | 71,631         |
| 7(b)                   | 26,789,248 | 1,195,412                            | 144,770        | 55,131         |
| 7(c)                   | 26,772,748 | 1,195,412                            | 196,770        | 19,631         |
| 7(d)                   | 19,244,442 | 198,069                              | 411,257        | 617,500        |
| 7(e)                   | 19,187,298 | 198,069                              | 470,401        | 615,500        |

**ENDS**

Further information or for an interview:

Dr Steven Mercer  
CEO, Tissue Therapies Limited  
Telephone: (07) 3839 9938

## **About Tissue Therapies Limited**

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic skin ulcers and burns.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)